Dossa Fahima, Baxter Nancy N, Sutradhar Rinku, Little Tari, Velsher Lea, Lerner-Ellis Jordan, Eisen Andrea, Metcalfe Kelly
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia.
Curr Oncol. 2025 Aug 6;32(8):439. doi: 10.3390/curroncol32080439.
To effectively reduce cancer burden, genetic testing programs should identify high-risk individuals prior to cancer development, when risk-reduction strategies can be implemented. We evaluated trends in / testing use after implementation of a publicly funded testing program.
We conducted a retrospective, near population-based study of women who underwent / testing in Ontario, Canada, (2007-2016) ( = 15,986). Temporal trends were evaluated using linear and Poisson regression.
Although annual utilization of testing increased over time ( < 0.001), mean age at testing increased from 49.9 years (SD 13.8) in 2007 to 53.8 years (SD 13.7) in 2016 ( < 0.001). The proportion of women with a cancer history at testing also increased from 53.5% in 2007 to 66.3% in 2015 ( < 0.001); the proportion of women free from breast cancer did not change significantly (49.2% in 2007 versus 45.1% in 2015, = 0.90). As a proportion of all tested, those with breast cancer tested within 3 months of diagnosis increased over time (0.39% of tests in 2007 versus 13.6% of tests in 2015; < 0.001).
While the institution of a publicly funded genetic testing program was associated with rising utilization, increasing age at testing and decreasing testing of unaffected women suggest limitations in identifying high-risk individuals eligible for risk-reduction.
为有效减轻癌症负担,基因检测项目应在癌症发生前识别出高危个体,以便实施降低风险策略。我们评估了一项公共资助检测项目实施后基因检测的使用趋势。
我们对加拿大安大略省(2007 - 2016年)接受基因检测的女性进行了一项回顾性、近乎基于人群的研究(n = 15,986)。使用线性回归和泊松回归评估时间趋势。
尽管基因检测的年使用率随时间增加(P < 0.001),但检测的平均年龄从2007年的49.9岁(标准差13.8)增加到2016年的53.8岁(标准差13.7)(P < 0.001)。检测时有癌症病史的女性比例也从2007年的53.5%增加到2015年的66.3%(P < 0.001);无乳腺癌的女性比例没有显著变化(2007年为49.2%,2015年为45.1%,P = 0.90)。作为所有检测者的比例,那些在诊断后3个月内进行检测的乳腺癌患者随时间增加(2007年检测的0.39% vs 2015年检测的13.6%;P < 0.001)。
虽然公共资助基因检测项目的设立与使用率上升有关,但检测年龄增加和未受影响女性检测减少表明在识别符合降低风险条件的高危个体方面存在局限性。